Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seaside Therapeutics makes board appointments

This article was originally published in Scrip

Executive Summary

Seaside Therapeutics (US) has appointed Marc Beer, former CEO of ViaCell, Karen Dawes, president of Knowledge Decisions, and Dr Steven Paul, former executive vice-president for science and technology at Lilly, to its board of directors. They join Seaside's current board members – the company's president & CEO, Dr Randall Carpenter, and Peter Whipp, managing director of Barony Trust, Seaside's largest investor. Seaside is creating treatments to correct or improve the course of fragile X syndrome, autism and other neurodevelopmental disorders.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC009627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel